Harmony raises $270M, licenses narcolepsy drug

On Oct. 6, CNS company Harmony Biosciences LLC (Plymouth Meeting, Pa.) said it raised $270 million in an equity round from Valor Equity Partners, Fidelity Management & Research Co., HBM Healthcare Investments, Vivo Capital, venBio, Novo Holdings A/S (Hellerup, Denmark) and Nan Fung Life Sciences.

Harmony also obtained exclusive, U.S. rights to develop and commercialize pitolisant (BF2.649) from Bioprojet SCR (Paris, France), which markets the drug in the EU to treat narcolepsy. Harmony declined to discuss specific terms of the companies' deal...